Peter Atadja

FAQ About Peter Atadja

• What is Peter Atadja's address?

  Peter Atadja is located at
  Greater Boston, Greater Boston, United States

• What is Peter Atadja's job title?

  Peter Atadja is a
  I am an accomplished and visionary leader in drug discovery with over 20 years’ experience in the global pharmaceutical industry. Highly productive in both start-up and mature environments. Now working at Landcent to accelerate the fight against diseases of poverty. • Pioneer in Epigenetics of Cancer Drug Discovery and Development. • Advanced multiple first in class NMEs against unprecedented and previously unexplored targets from inception through IND submission and clinical development. Opened up a number of novel pathways and biology for drug discovery. • Led the discovery and development of LBH589/Panobinostat (HDACi) from scientific concept through all phases of discovery and development to achieve the first ever FDA-approved epigenetic therapy (FARYDAKTM) for relapsed/refractory Multiple Myeloma. • Co-founded Novartis’ third global R&D center (CNIBR) in Shanghai China. Established a highly productive drug discovery and translational research program and delivered multiple novel targets and first-in-class drug candidates into the Novartis global pipeline. • Contributed >120 peer-reviewed articles, critical reviews and book chapters to Cancer Biology, Drug Discovery and Development literature • Inventor/co-inventor of multiple patents. • Recipient of Novartis’ highest global Award for Drug Discovery (The 2008 VIVA AWARD) Landcent Europe

• What industry does Peter Atadja currently work in?

  Peter Atadja currently works in the
  Landcent Europe

• What is Peter Atadja's area of expertise?

  Peter Atadja specializes in
  I am an accomplished and visionary leader in drug discovery with over 20 years’ experience in the global pharmaceutical industry. Highly productive in both start-up and mature environments. Now working at Landcent to accelerate the fight against diseases of poverty. • Pioneer in Epigenetics of Cancer Drug Discovery and Development. • Advanced multiple first in class NMEs against unprecedented and previously unexplored targets from inception through IND submission and clinical development. Opened up a number of novel pathways and biology for drug discovery. • Led the discovery and development of LBH589/Panobinostat (HDACi) from scientific concept through all phases of discovery and development to achieve the first ever FDA-approved epigenetic therapy (FARYDAKTM) for relapsed/refractory Multiple Myeloma. • Co-founded Novartis’ third global R&D center (CNIBR) in Shanghai China. Established a highly productive drug discovery and translational research program and delivered multiple novel targets and first-in-class drug candidates into the Novartis global pipeline. • Contributed >120 peer-reviewed articles, critical reviews and book chapters to Cancer Biology, Drug Discovery and Development literature • Inventor/co-inventor of multiple patents. • Recipient of Novartis’ highest global Award for Drug Discovery (The 2008 VIVA AWARD)

• Which languages does Peter Atadja speak? 

  Peter Atadja speaks the following languages:
  No languages available.

• Which industries has Peter Atadja previously worked in?   

  Peter Atadja has prior experience in the following industries:
  Landcent Europe , Novartis , Novartis , Novartis

• What is Peter Atadja’s work experience?  

  Peter Atadja has the following professional experience:
  Landcent Europe , Landcent Europe , Novartis , Novartis , Novartis .

• How can I find Peter Atadja on LinkedIn?  

  You can view Peter Atadja’s
  LinkedIn profile at LinkedIn URL.

• What are Peter Atadja’s work email addresses?  

  Peter Atadja’s work email addresses are
  [email protected] .

• What company does Peter Atadja work for?  

  Peter Atadja works at
  Landcent Europe